Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Oct 31, 2022

SELL
$144.95 - $152.29 $1.36 Million - $1.43 Million
-9,396 Reduced 46.56%
10,786 $1.63 Million
Q2 2022

Jul 29, 2022

BUY
$83.14 - $145.99 $724,481 - $1.27 Million
8,714 Added 75.99%
20,182 $2.94 Million
Q1 2022

Apr 29, 2022

SELL
$110.08 - $142.92 $903,756 - $1.17 Million
-8,210 Reduced 41.72%
11,468 $1.36 Million
Q4 2021

Feb 07, 2022

SELL
$99.73 - $148.48 $33,509 - $49,889
-336 Reduced 1.68%
19,678 $2.71 Million
Q3 2021

Nov 01, 2021

BUY
$98.85 - $138.91 $1.06 Million - $1.49 Million
10,709 Added 115.09%
20,014 $2.78 Million
Q2 2021

Aug 12, 2021

BUY
$65.78 - $105.02 $31,048 - $49,569
472 Added 5.34%
9,305 $903,000
Q1 2021

May 13, 2021

SELL
$64.07 - $91.75 $116,799 - $167,260
-1,823 Reduced 17.11%
8,833 $604,000
Q4 2020

Feb 04, 2021

SELL
$65.07 - $98.24 $216,487 - $326,844
-3,327 Reduced 23.79%
10,656 $913,000
Q3 2020

Nov 09, 2020

BUY
$59.04 - $77.95 $369,118 - $487,343
6,252 Added 80.87%
13,983 $909,000
Q2 2020

Jul 20, 2020

SELL
$29.01 - $74.23 $641,033 - $1.64 Million
-22,097 Reduced 74.08%
7,731 $565,000
Q1 2020

Apr 30, 2020

BUY
$27.51 - $57.29 $759,165 - $1.58 Million
27,596 Added 1236.38%
29,828 $1.02 Million
Q4 2019

Jan 28, 2020

BUY
$40.86 - $57.65 $91,199 - $128,674
2,232 New
2,232 $122,000
Q2 2019

Jul 29, 2019

SELL
$39.79 - $67.01 $445,488 - $750,243
-11,196 Closed
0 $0
Q1 2019

Apr 29, 2019

SELL
$34.52 - $53.29 $86,334 - $133,278
-2,501 Reduced 18.26%
11,196 $576,000
Q4 2018

Feb 01, 2019

BUY
$29.75 - $42.9 $407,485 - $587,601
13,697 New
13,697 $507,000
Q3 2018

Nov 06, 2018

SELL
$32.79 - $43.0 $158,244 - $207,518
-4,826 Closed
0 $0
Q2 2018

Aug 07, 2018

BUY
$23.62 - $42.29 $113,990 - $204,091
4,826 New
4,826 $191,000

Others Institutions Holding BHVN

About Biohaven Pharmaceutical Holding Co Ltd.


  • Ticker BHVN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,645,000
  • Market Cap $3.65B
  • Description
  • Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...
More about BHVN
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.